No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following ...

The Company enters 2026 with Multiple Phase 2 Catalysts collectively representing ~$8 billion in potential market ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to ...

Allucent has strategically added executives to its C-suite and is deploying artificial intelligence tools to help small and ...

YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic ...

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...

The Agency for Health Care Administration revised the public notice published Sept. 30, 2025, in Vol. 51 No. 190 of the ...

AI emerged as a key differentiator in accelerating development timelines and enhancing clinical operations. Decentralized ...

Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) ('Polyrizon” or the 'Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from ...

CYB003/CYB004 clinical catalysts into 2026, $248M cash runway, equity raises risk, valuation optionality. Click for this CYBN ...

FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures ...